D. K. Lahiri ET AL: "The Experimental Alzheimer's Disease Drug Posiphen [(+)-Phenserine] Lowers Amyloid-beta Peptide Levels in Cell Culture and Mice", Journal of Pharmacology and Experimental Therapeutics, vol. 320, no. 1, 27 June 2006 (2006-06-27) , pages 386-396, XP055130741, ISSN: 0022-3565, DOI: 10.1124/jpet.106.112102 (B8)

HAROLD W HOLLOWAY ET AL: "Posiphen and Analogs: Experimental Alzheimer Agents that Reduce Amyloid-[beta] Peptide by Lowering Amyloid Precursor Protein Levels in Culture and In Vivo", 42ND ANNUAL WINTER CONFERENCE ON BRAIN RESEARCH, 25 January 2009 (2009-01-25), XP055130785, 42nd Annual Winter Conference on Brain Research (B8)

Jack T. Rogers ET AL: "The alpha-synuclein 5'untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen", Journal of Neural Transmission, vol. 118, no. 3, 8 January 2011 (2011-01-08), pages 493-507, XP055625613, Vienna ISSN: 0300-9564, DOI: 10.1007/s00702-010-0513-5 (B8)

KADIR A ET AL: "Long-term effect of phenserine treatment in Alzheimer patients as assessed by PET and CSF biomarkers", ALZHEIMER'S & DEMENTIA: THE JOURNAL OF THE ALZHEIMER'SASSOCIATION, ELSEVIER, NEW YORK, NY, US, vol. 5, no. 4, 1 July 2009 (2009-07-01), page P6, XP026897327, ISSN: 1552-5260, DOI: 10.1016/J.JALZ.2009.05.019 [retrieved on 2009-07-01] (B8)

MACCECCHINI ET AL.: 'Posiohen lowers amyloid precursor protein and amyloid beta as well as acetylcholinesterase levels in culture, animals and humans' INTERNATIONAL CONFERENCE ON ALZHEIMER'S DISEASE vol. 5, no. 4, 12 July 2009, XP026253808 Retrieved from the Internet: <URL:http://www.qrpharma.com/pdf/ICAD_Posip hen_06-30-2009.pdf> [retrieved on 2012-05-19] (B8)

Maria L Maccecchini ET AL: "Posiphen: Experimental Alzheimer Agent that Lowers Amyloid Precursor Protein Levels in Culture and In Vivo", , 12 July 2009 (2009-07-12), XP055130786, International Conference on Alzheimer's Disease Retrieved from the Internet: URL:http://www.qrpharma.com/pdf/ICAD_Posip hen_06-30-2009.pdf [retrieved on 2014-07-22] (B8)

WO-A2-2010/117727 (B8)

Maria Maccecchini ET AL: "Targeting Alzheimer's with Novel Therapuetics", , 11 May 2010 (2010-05-11), XP055130807, Neuroscience Network Retrieved from the Internet: URL:http://www.qrpharma.com/pdf/2010-5-11 Alzheimers Research Today Maria Maccecchini slides.pdf [retrieved on 2014-07-22] (B8)

U.S. Department Of Health And Human Services Food And Drug Administration Center For Drug Evaluation And Research (cder): "Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers", , 6 July 2005 (2005-07-06), XP055568568, Retrieved from the Internet: URL:https://www.fda.gov/downloads/Drugs/Gu idances/UCM078932.pdf#search='guidekines+f or+industry+sfe+starting' [retrieved on 2019-03-13] (B8)

US-A1- 2002 094 999 (B8)

US-A1- 2005 013 869 (B8)

WO-A1-2005/089746 (B8)

Maria L. Maccecchini: "Mechanism of Action of Posiphen : From Model to Human", , 26 January 2011 (2011-01-26), XP055130818, 44nd Annual Winter Conference on Brain Research Retrieved from the Internet: URL:http://www.qrpharma.com/pdf/WCBR Talk Jan 2011.pdf [retrieved on 2014-07-22] (B8)